These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 17706532)
1. Normal and abnormal patterns of 18F-fluorodeoxyglucose PET/CT in lymphoma. Bar-Shalom R Radiol Clin North Am; 2007 Jul; 45(4):677-88, vi-vii. PubMed ID: 17706532 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of [18F]-FDG-Based Hybrid Imaging Combinations for Assessment of Bone Marrow Involvement in Lymphoma at Initial Staging. Asenbaum U; Nolz R; Karanikas G; Furtner J; Woitek R; Staudenherz A; Senn D; Raderer M; Weber M; Simonitsch-Klupp I; Mayerhoefer ME PLoS One; 2016; 11(10):e0164118. PubMed ID: 27723817 [TBL] [Abstract][Full Text] [Related]
3. [Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas]. Qiao WL; Zhao JH; Wang C; He ZY; Wang TS; Xing Y Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):536-9. PubMed ID: 18069637 [TBL] [Abstract][Full Text] [Related]
4. Accuracy of whole-body 18F-FDP-PET for restaging malignant lymphoma. Mikosch P; Gallowitsch HJ; Zinke-Cerwenka W; Heinisch M; Pipam W; Eibl M; Kresnik E; Unterweger O; Linkesch W; Lind P Acta Med Austriaca; 2003; 30(2):41-7. PubMed ID: 12752087 [TBL] [Abstract][Full Text] [Related]
5. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer. Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493 [TBL] [Abstract][Full Text] [Related]
6. PET/computed tomography and lymphoma. Allen-Auerbach M; de Vos S; Czernin J Radiol Clin North Am; 2013 Sep; 51(5):833-44. PubMed ID: 24010908 [TBL] [Abstract][Full Text] [Related]
7. The role of FDG-PET imaging in the management of lymphoma. Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171 [TBL] [Abstract][Full Text] [Related]
8. [Positron emission tomography (PET) with [18F]-FDG in bronchopulmonary cancer and its impact on medical decision at the time of diagnosis, staging, or recurrence evaluation]. Grahek D; Montravers F; Mayaud C; Regnard JF; Kerrou K; Younsi N; Talbot JN Rev Pneumol Clin; 2001 Dec; 57(6):393-403. PubMed ID: 11924148 [TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose. Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554 [TBL] [Abstract][Full Text] [Related]
10. PET and PET/CT in management of the lymphomas. Podoloff DA; Macapinlac HA Radiol Clin North Am; 2007 Jul; 45(4):689-96, vii. PubMed ID: 17706533 [TBL] [Abstract][Full Text] [Related]
12. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Moog F; Bangerter M; Diederichs CG; Guhlmann A; Kotzerke J; Merkle E; Kolokythas O; Herrmann F; Reske SN Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707 [TBL] [Abstract][Full Text] [Related]
13. [Computerized tomography and F-18-FDG positron emission tomography in staging of malignant lymphomas: a comparison]. Bumann D; de Wit M; Beyer W; Beese M; Lübeck M; Bücheler E; Clausen M Rofo; 1998 May; 168(5):457-65. PubMed ID: 9617362 [TBL] [Abstract][Full Text] [Related]
14. Spectrum of (18)F-FDG PET/CT appearances in peritoneal disease. Anthony MP; Khong PL; Zhang J AJR Am J Roentgenol; 2009 Dec; 193(6):W523-9. PubMed ID: 19933627 [TBL] [Abstract][Full Text] [Related]
15. Comparison of 18F-FDG Pet/CT and CT: diagnosis performance in lymphoma patient after treatment. Chiewvit S; Thephamongkhol K; Ubolnuch K; Pooliam J; Phongsawat N; Chiewvit P J Med Assoc Thai; 2014 Jan; 97(1):85-94. PubMed ID: 24701734 [TBL] [Abstract][Full Text] [Related]
16. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771 [TBL] [Abstract][Full Text] [Related]
17. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions? Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088 [TBL] [Abstract][Full Text] [Related]
18. 18F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma. Rini JN; Leonidas JC; Tomas MB; Palestro CJ J Nucl Med; 2003 Jul; 44(7):1072-4. PubMed ID: 12843223 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients. Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Pinker-Domenig K; Berzaczy D; Hoffmann M; Sillaber C; Jaeger U; Müllauer L; Simonitsch-Klupp I; Dolak W; Gaiger A; Ubl P; Lukas J; Raderer M Clin Cancer Res; 2014 Jun; 20(11):2984-93. PubMed ID: 24696320 [TBL] [Abstract][Full Text] [Related]
20. Diagnostic Yield of Body CT and Whole-Body FDG PET/CT for Initial Systemic Staging in Patients With Suspected Primary CNS Lymphoma: A Systematic Review and Meta-Analysis. Park HY; Suh CH; Huang RY; Guenette JP; Kim HS AJR Am J Roentgenol; 2021 May; 216(5):1172-1182. PubMed ID: 32812800 [No Abstract] [Full Text] [Related] [Next] [New Search]